Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.

MLA

Goswami, Hardik, et al. “Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.” PharmacoEconomics, vol. 40, no. 7, July 2022, pp. 699–714. EBSCOhost, https://doi.org/10.1007/s40273-022-01168-0.

APA

Goswami, H., Alsumali, A., Jiang, Y., Schindler, M., Duke, E. R., Cohen, J., Briggs, A., & Puenpatom, A. (2022). Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US. PharmacoEconomics, 40(7), 699–714. https://doi.org/10.1007/s40273-022-01168-0

Chicago

Goswami, Hardik, Adnan Alsumali, Yiling Jiang, Matthias Schindler, Elizabeth R. Duke, Joshua Cohen, Andrew Briggs, and Amy Puenpatom. 2022. “Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.” PharmacoEconomics 40 (7): 699–714. doi:10.1007/s40273-022-01168-0.